P2Add image
PE-22-28
CognitiveSingleA synthetic analog of the spadin peptide, studied as a fast-acting antidepressant via TREK-1 channel blockade.
Half-life
—
Common dose
250 – 500 mcg
Dosing frequency
Daily
Administration
Subcutaneous, Intranasal
How it works
PE-22-28 blocks TREK-1 potassium channels, a target implicated in depression resistance. Animal studies suggest antidepressant effects on the order of days rather than weeks.
Protocol notes
Research protocols dose 250–500 mcg daily subcutaneously or intranasally for 4–6 weeks. Limited human data — most evidence is preclinical.
Reported side effects
Limited safety data in humans. Possible mood instability, fatigue, headache.